BioSpace News Archive

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that the Company’s founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition.

Paratek Pharmaceuticals, Inc. announced two key executive team promotions.

Dewpoint Therapeutics Inc. announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.

The Journal of Prevention of Alzheimer’s Disease (JPAD) with the support of the Alzheimer’s Drug Discovery Foundation (ADDF) recently published a comprehensive issue, “The Biology of Aging: Leading The Next Generation of Alzheimer’s Drug Development With a Geroscience Focus,” which supports the consensus that combination therapy and precision medicine are the future of Alzheimer’s treatment.

Aspen Neuroscience, Inc. announced the appointment of Ana Sousa, MSJ as the company’s Chief Regulatory Officer.

Noctrix Health, Inc. announced today that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation with strong support from insiders including OrbiMed and Treo Ventures.

Non-invasive cardiac assessment company Sensydia announced that it has completed its 50-subject development study at the University of Minnesota.

Therapeutic Solutions International, Inc. announced the formation of Epilepsy Bio, Inc., a subsidiary company dedicated to commercializing intellectual property, clinical, and mechanistic findings associated with cellular and immunological approaches to epilepsy.

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), (“Braxia Scientific”, or the “Company”), a medical research company with clinics providing innovative ketamine

Kairos Pharma, Ltd. announces the dosing of its first two patients in its Phase 1 trial testing a combination therapy for its lead therapeutic candidate ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer.